Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.

The Journal of rheumatology - 1 Apr 2007

Singh Gurmeet, Saxena Nandita, Aggarwal Amita, Misra Ramnath

Abstract excerpt

OBJECTIVE: Ovarian toxicity is a major concern with cyclophosphamide (CYC) therapy. CYC is a prodrug that is activated by cytochrome P450 (CYP) enzymes to its active metabolites that are responsible for ovarian toxicity. The amount of active metabolites produced depends on polymorphism in CYP 450 genes. We studied the association of CYP2C19 and CYP2B6 genetic polymorphism with ovarian toxicity in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 Enzyme System

Share to Lupus Erythematosus, Systemic

Share to Mixed Function Oxygenases

Share to Primary Ovarian Insufficiency

Source

Identifiers

PMID: 17407229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.PMID 17407229Read ↗

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Semantic proximity Read ↗

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Semantic proximity Read ↗

Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.Semantic proximity Read ↗

Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.Semantic proximity Read ↗

Exploring the Correlation Between Genotypes of Drug-Metabolizing Enzymes and the Therapeutic Efficacy and Adverse Reactions of Cyclophosphamide in Childhood-Onset Lupus Nephritis: A Chinese Cohort Study.Semantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.Semantic proximity Read ↗

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.Semantic proximity Read ↗

CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.Semantic proximity Read ↗

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.